Lyophilized, thermostable Spike or RBD immunogenic liposomes induce protective immunity against SARS-CoV-2 in mice

Autor: Victoria S. Cavener, Jonathan F. Lovell, Jean-Philippe Julien, Wei-Chiao Huang, Meera Surendran Nair, Ruth H. Nissly, Suresh V. Kuchipudi, Moustafa T. Mabrouk, Edurne Rujas, Joaquin Ortega, Kevin Chiem, Dushyant Jahagirdar, Breandan Quinn, Nina R. Boyle, Luis Martinez-Sobrido, Ty A Sornberger
Přispěvatelé: National Institutes of Health (US), European Commission, Canada Research Chairs, Canada Foundation for Innovation, McGill University, Mabrouk, Moustafa T. [0000-0001-5912-2406], Rujas, Edurne [0000-0002-4465-5071], Jahagirdar, Dushyant [0000-0003-4173-7378], Quinn, Breandan [0000-0002-0165-4650], Surendran Nair, Meera [0000-0003-4686-8414], Nissly, Ruth [0000-0002-3102-7447], Boyle, Nina [0000-0003-0901-3775], Sornberger, Ty [0000-0001-5483-1756], Kuchipudi, Suresh [0000-0002-8640-254X], Julien, Jean-Philippe [0000-0001-7602-3995], Martínez-Sobrido, Luis [0000-0001-7084-0804], Lovell, Jonathan [0000-0002-9052-884X], Mabrouk, Moustafa T., Rujas, Edurne, Jahagirdar, Dushyant, Quinn, Breandan, Surendran Nair, Meera, Nissly, Ruth, Boyle, Nina, Sornberger, Ty, Kuchipudi, Suresh, Julien, Jean-Philippe, Martínez-Sobrido, Luis, Lovell, Jonathan
Rok vydání: 2021
Předmět:
Zdroj: Digital.CSIC. Repositorio Institucional del CSIC
instname
Science Advances
Popis: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide viral pandemic leading to global efforts to produce and distribute effective vaccines that prevent coronavirus virus disease 2019 (COVID-19) (1). The Spike protein and, more specifically, its receptor-binding domain (RBD) on the virus surface are responsible for binding to human angiotensin-converting enzyme 2 (hACE2) on the host cell. Hence, because of their central role in viral entry, the Spike and the RBD are established immunogens in SARS-CoV-2 vaccines (2, 3). mRNA-based and viral-vectored vaccines encoding the Spike protein have gained regulatory approvals and are being massively deployed presently. Despite their excellent protective efficacy against SARS-CoV-2, mRNA vaccines have well-known limited thermostability, and thus, global distribution is complicated by the requirement of ultracold freezing storage temperatures (4). As COVID-19 vaccines are needed worldwide to immunize sufficient populations to induce global herd immunity, including in low- and middle-income countries, there is more demand for vaccine doses than at any other time in history (5). A potent vaccine that is effective with a lower amount of antigen per dose would increase manufacturing and distribution capacity, facilitating the supply of global needs during the pandemic.
This research was supported by the NIH (R43AI165089), the European Union’s Horizon 2020 research and innovation program under a Marie Skłodowska-Curie grant (E.R.), the CIFAR Azrieli Global Scholar program (J.P.-J.), the Ontario Early Researcher Awards program (J.P.-J.), and the Canada Research Chairs program (J.P.-J.). Cryo-EM images were collected at the Facility for Electron Microscopy Research (FEMR) at McGill University. FEMR is supported by the Canadian Foundation for Innovation, the Quebec government, and McGill University.
Databáze: OpenAIRE
Externí odkaz: